📰 Safety Analysis Set News
Safety Analysis Set News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Safety Analysis Set. Real-time updates on events, politics, business and more.
September 7, 2022
KITE’S  CAR  T-CELL  THERAPY  TECARTUS®  (BREXUCABTAGENE  AUTOLEUCEL)  GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF  RELAPSED  OR  REFRACTORY  ACUTE  LYMPHOBLASTIC  LEUKAEMIA  (r/r ALL) -- Approval Marks Kite’...
July 22, 2022
KITE’S  CAR  T-CELL  THERAPY  TECARTUS®  (BREXUCABTAGENE  AUTOLEUCEL)  RECEIVES  POSITIVE  CHMP  OPINION  IN  RELAPSED  OR  REFRACTORY  ACUTE  LYMPHOBLASTIC  LEUKAEMIA  (r/r ALL) –  Tecartus® (Brex...
December 7, 2021
/PRNewswire/ -- Eisai Inc. presented data from PERMIT, a large real-world clinical study evaluating its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII,...
December 7, 2021
/PRNewswire/ -- Eisai Inc. presented data from PERMIT, a large real-world clinical study evaluating its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII,...
October 1, 2021
In a phase 2 randomized placebo-controlled trial, Neil Formica and coauthors investigate the immunogenicity and safety of different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine in younger and older adults in USA and Australia.